No need for waffling here—ENTA is cheap! As previously noted, if ABT-450 merely gets approved but never sells even a dollar’s worth of product, ENTA will earn contractual milestone payments from ABBV that are worth roughly the same as ENTA's current enterprise value.
Moreover, antiviral drugs don’t fail phase-3 trials due to inadequate efficacy, so the only reason ABT-450 might not get approved is if a serious safety problem surfaces that hasn’t been seen before. Possible but not likely, IMO.
Market Data 
Markets 
AI
